The obesity drug pipeline has exploded. In the past year alone, the US approved the first two weight-loss pills: the Wegovy pill (oral semaglutide, December 2025) and Foundayo (orforglipron, April 2026). Novo Nordisk filed CagriSema, a combination of semaglutide and the amylin analog cagrilintide, with the FDA in December 2025. Lilly’s triple agonist retatrutide posted the biggest numbers ever seen (28.3% at 80 weeks) and is headed for filing in early 2027.
The trend is clear: more weight loss (retatrutide, CagriSema), easier delivery (pills, monthly shots) and new mechanisms (amylin, glucagon) that may be gentler or better at preserving muscle. Here is every major drug, what the data show, and what is likely to reach Canada, and when.
The pipeline at a glance
| Drug | Company | Type | Status (Oct 2026) | Headline weight loss |
|---|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | Novo Nordisk | Daily pill, GLP-1 | FDA-approved Dec 2025 | 13.6% at 64 weeks |
| Foundayo (orforglipron) | Eli Lilly | Daily pill, non-peptide GLP-1 | FDA-approved Apr 2026 | Up to 12.4% at 72 weeks |
| CagriSema | Novo Nordisk | Weekly injection, GLP-1 + amylin | Filed with FDA Dec 2025 | 20.4–22.7% at 68 weeks |
| Retatrutide | Eli Lilly | Weekly injection, GLP-1 + GIP + glucagon | FDA filing planned Q1 2027 | 28.3% at 80 weeks |
| Survodutide | Boehringer Ingelheim | Weekly injection, GLP-1 + glucagon | Phase 3 reported 2026 | 12–13% at 76 weeks |
| Amycretin | Novo Nordisk | GLP-1 + amylin in one molecule | Phase 3 | Large losses in early trials |
| MariTide | Amgen | Monthly injection | Phase 3 | Up to about 20% in phase 2 |
Approved options today, in Canada, remain semaglutide (Ozempic, Wegovy and the new generics), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda). See weight loss injections in Canada for prices and coverage.
Four mechanisms, explained simply
| Hormone pathway | Natural source | What it adds |
|---|---|---|
| GLP-1 | Gut | Appetite reduction, slower stomach emptying, insulin release. The backbone of every drug here. |
| GIP | Gut | Improves insulin and fat metabolism; may reduce nausea. Added in tirzepatide and retatrutide. |
| Glucagon | Pancreas | Raises energy expenditure and clears liver fat. Added in retatrutide and survodutide. |
| Amylin | Pancreas (with insulin) | Fullness via a separate brain pathway; slows stomach emptying. Added in CagriSema and amycretin. |
The design logic: stacking pathways that reduce appetite or raise energy use in different ways produces more weight loss than pushing one pathway harder, which mostly adds side effects.
The pills: Wegovy pill and Foundayo
Wegovy pill (oral semaglutide 25 mg)
Oral semaglutide has existed for diabetes (Rybelsus), but at lower strengths. A higher-strength, once-daily pill was approved by the US FDA for weight management in December 2025. In the OASIS 4 trial, it produced 13.6% average weight loss at 64 weeks versus 2.2% on placebo. Because semaglutide is a peptide that is fragile in the stomach, oral versions require specific administration conditions to absorb, typically on an empty stomach with limited water and waiting before eating.
Foundayo (orforglipron)
Orforglipron is different: it is a small molecule, not a peptide, that activates the GLP-1 receptor. That means it survives digestion and can be taken without food or water restrictions, and it is far cheaper to manufacture at scale than peptides. The FDA approved it as Foundayo in April 2026. In ATTAIN-1, weight loss reached up to 12.4% at 72 weeks on the highest dose. The most common side effects were gastrointestinal, similar to injectable GLP-1s.
Pills produce somewhat less weight loss than the strongest injections, but they remove needle barriers, are easier to ship and store (no refrigeration), and could be manufactured in far larger quantities, which may eventually lower prices and widen access.
CagriSema: semaglutide plus amylin
CagriSema combines semaglutide with cagrilintide, a long-acting analog of amylin, in a once-weekly injection. Amylin is a hormone co-released with insulin after meals that signals fullness through a different brain pathway from GLP-1.
| Trial | Population | Length | CagriSema | Placebo |
|---|---|---|---|---|
| REDEFINE 1 | Obesity, no diabetes | 68 weeks | 20.4% (22.7% if taken as intended) | 3.0% |
| REDEFINE 2 | Type 2 diabetes + obesity | 68 weeks | 13.7% | 3.4% |
REDEFINE 1 also included arms of semaglutide alone and cagrilintide alone, and the combination beat both, showing the two hormones add to each other (REDEFINE 1, 2025). Gastrointestinal side effects were common: about 80% of CagriSema participants reported at least one, versus 40% on placebo, mostly mild to moderate and during dose escalation.
Novo Nordisk filed CagriSema with the FDA in December 2025. The results came in a little below the 25% the company originally hoped for, but an amylin-based combination may offer advantages in tolerability and in the quality of weight loss, which researchers are still exploring.
Cagrilintide on its own
Cagrilintide alone produces meaningful but smaller weight loss than semaglutide. Its interest lies in how it works: amylin analogs reduce food intake and may produce a more favourable mix of fat versus lean tissue loss, and they reduce appetite with a different side-effect profile. That is why it is mainly being developed in combinations. We cover its trial data in the cagrilintide research guide.
Retatrutide: the triple agonist
Retatrutide adds glucagon to GLP-1 and GIP. Its phase 3 program has delivered the strongest results in the field:
- TRIUMPH-1: 19.0%, 25.9% and 28.3% average weight loss at 80 weeks across doses; 30.3% at 104 weeks in an extension.
- TRIUMPH-2 (type 2 diabetes): up to 20.8%.
- TRIUMPH-3 (heart disease): up to 22.6%.
- TRIUMPH-4 (knee arthritis): up to 28.7%, with reduced knee pain.
Trade-offs include more GI side effects and dropouts at the top dose and a new signal of dysesthesia (unusual skin sensations). Lilly plans to file with the FDA in the first quarter of 2027. Every trial is broken down in our retatrutide phase 3 results guide.
Survodutide: GLP-1 plus glucagon
Boehringer Ingelheim’s survodutide combines GLP-1 and glucagon activity (without GIP). Its glucagon component has made it a strong candidate for fatty liver disease. In the SYNCHRONIZE-1 phase 3 trial in 725 adults with obesity, weight loss was about 12% to 13% at 76 weeks versus 5% on placebo, more modest than many expected, and a substantial share of participants discontinued treatment. Its future may lie more in liver disease than in pure weight loss. See our fatty liver treatment guide.
Amycretin: amylin and GLP-1 in one molecule
Rather than combining two drugs like CagriSema, amycretin is a single molecule that activates both GLP-1 and amylin receptors. Novo Nordisk has tested both weekly injections and a daily pill, and early-phase results reported large weight losses over relatively short treatment periods, prompting a move into later-stage trials. It is several years from possible approval.
Monthly injections: MariTide
Amgen’s MariTide (maridebart cafraglutide) takes an unusual approach: an antibody-based drug that activates GLP-1 receptors while blocking GIP receptors, given once a month. In phase 2, average weight loss reached about 20% at 52 weeks in people without diabetes. Phase 3 trials are underway. A monthly schedule could improve adherence, though early trials reported notable nausea and vomiting with initial doses.
Muscle-sparing add-ons
A parallel race is about the quality of weight loss. The most advanced example is bimagrumab, an antibody that blocks activin type II receptors (brakes on muscle growth). In the BELIEVE trial, adding it to semaglutide produced 22.1% weight loss with only about 7% of it lean mass, versus about 28% lean mass with semaglutide alone. More in muscle loss on GLP-1 drugs.
Side-by-side comparison
| Drug | How often | Delivery | Weight loss (main trial) | Distinguishing feature |
|---|---|---|---|---|
| Wegovy (injection) | Weekly | Injection | ~15% | Proven cardiovascular benefit; generics in Canada |
| Zepbound | Weekly | Injection | ~21% | Most effective approved option in Canada |
| Wegovy pill | Daily | Pill | 13.6% | Administration conditions for absorption |
| Foundayo | Daily | Pill | Up to 12.4% | No food or water restrictions; small molecule |
| CagriSema | Weekly | Injection | 20.4–22.7% | Adds amylin pathway |
| Retatrutide | Weekly | Injection | 28.3% | Highest weight loss; liver fat clearance |
| Survodutide | Weekly | Injection | 12–13% | Focus on liver disease |
| MariTide | Monthly | Injection | ~20% (phase 2) | Monthly dosing |
Figures come from different trials with different populations and durations, so they are not a head-to-head ranking.
What reaches Canada, and when
Health Canada reviews drugs independently, and new obesity drugs have typically reached Canada after the US:
- The pills (Wegovy pill, Foundayo) are the most likely next arrivals. Check Health Canada’s Drug Product Database or ask your pharmacist for current status, since submissions aren’t always public until approval.
- CagriSema could follow its US decision.
- Retatrutide: a US filing in early 2027 points to a realistic Canadian timeline in 2028 or later. Our approval tracker has the latest.
- Generic semaglutide is already here and has transformed the cost picture for Canadians.
Will prices come down?
Several forces are pushing prices down: generic semaglutide in Canada since May 2026, competition between Novo Nordisk and Lilly, and small-molecule pills that are much cheaper to manufacture. New brand-name drugs usually launch at premium prices, so the newest options are unlikely to be cheap at first. Public coverage for obesity treatment in Canada remains limited, though it’s an active policy debate.
What this means if you’re choosing today
- Don’t wait for the perfect drug if you need treatment now. Approved options work well, and generics have made semaglutide much more affordable.
- Ask about tirzepatide if you need the most weight loss available today.
- Ask about the pills once available in Canada if needles are a barrier.
- Avoid grey-market versions of pipeline drugs: what is sold online as “retatrutide” or “cagrilintide” is an unregulated research chemical, not the medicine studied in trials.
- Protect muscle with strength training and protein, whichever drug you use.
Research compounds
For laboratory research, TrueLabs supplies several of the peptides behind these programs, with independent lab reports in our COA library. They are research chemicals, not medicines, and not for human use.
| Research compound | Pathway | From |
|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon | $90 |
| Tirzepatide | GLP-1 + GIP | $73 |
| Cagrilintide | Amylin | $40 |
| AOD-9604 | Growth hormone fragment (lipolysis research) | $23 |
Which type of drug might suit whom
No drug is best for everyone. This is how clinicians are starting to think about the options, as they become available:
| Situation | Options often considered |
|---|---|
| Needs the most weight loss available today | Tirzepatide (Zepbound) |
| Established heart disease | Semaglutide (proven cardiovascular benefit in SELECT) |
| Cost is the main barrier | Generic semaglutide in Canada |
| Dislikes needles | Oral options (Wegovy pill, Foundayo) where available |
| Type 2 diabetes | Semaglutide or tirzepatide, often covered for diabetes |
| Fatty liver with fibrosis | Semaglutide (Wegovy has conditional MASH approval in Canada) |
| Knee osteoarthritis and obesity | Semaglutide (STEP 9), tirzepatide; retatrutide data pending approval |
| Severe obesity, very high weight-loss goals | Tirzepatide now; retatrutide or CagriSema if approved; bariatric surgery |
These are general patterns, not recommendations; the right choice depends on your health history, coverage and preferences, decided with a prescriber.
Safety signals across the whole class
Incretin-based drugs share a set of known risks, and newer drugs will be watched for the same issues:
- Gastrointestinal effects: nausea, vomiting, diarrhea, constipation. The most common reason people stop.
- Gallbladder problems: gallstones are more common with rapid weight loss.
- Pancreatitis: rare; people with a history of pancreatitis are usually excluded.
- Thyroid C-cell tumours: seen in rodents; these drugs are not used in people with a personal or family history of medullary thyroid cancer or MEN2.
- Aspiration risk during anaesthesia: slowed stomach emptying means many surgical teams ask patients to pause these drugs before procedures.
- Dehydration and kidney strain with severe vomiting or diarrhea.
- Muscle and bone loss alongside fat loss (see muscle loss on GLP-1 drugs).
- Hair shedding from rapid weight loss (see hair loss on GLP-1 drugs).
- New signals to watch: dysesthesia with retatrutide, and heart rate effects with glucagon-containing drugs.
New weight loss drug myths
- “The next drug will make the current ones obsolete.” Current drugs have the longest safety records and, for semaglutide, proven heart benefits.
- “Pills are as strong as injections.” Current pills produce somewhat less weight loss than the strongest weekly injections.
- “Combination drugs mean double the side effects.” Not necessarily; combining pathways can allow more effect at tolerable doses, though GI effects remain common.
- “You can stop once you hit your goal weight.” For all of these drugs, weight tends to return after stopping.
- “Grey-market versions are the same as the trial drugs.” They are unregulated research chemicals.
- “New means safer.” Newer drugs simply have less long-term safety data.
Talking to your doctor about switching
If you’re already on a GLP-1 drug, questions worth asking:
- Am I getting enough benefit from my current drug and dose?
- Would switching to tirzepatide or a newer option add meaningful benefit for my goals?
- Is generic semaglutide an option to lower my cost?
- Are my side effects manageable, or would another drug suit me better?
- How would switching affect my coverage?
- What’s the plan for maintaining weight long-term?
A short history: 2005 to 2028
| Year | Milestone |
|---|---|
| 2005 | Exenatide, the first GLP-1 drug, approved for type 2 diabetes in the US |
| 2014–2015 | Liraglutide (Saxenda) approved for weight management |
| 2017–2018 | Semaglutide (Ozempic) approved for diabetes |
| 2021 | Wegovy approved for weight management in the US; STEP 1 published |
| 2022 | Tirzepatide (Mounjaro) approved for diabetes; SURMOUNT-1 published |
| 2023 | SELECT shows cardiovascular benefit; retatrutide phase 2 published |
| 2025 | Zepbound approved in Canada; CagriSema phase 3 published; Wegovy pill approved in the US |
| 2026 | Generic semaglutide in Canada; Foundayo approved in the US; retatrutide phase 3 results |
| 2027 (planned) | Retatrutide FDA filing |
The pace is remarkable: in about 20 years, the field went from a diabetes drug derived from lizard venom (exenatide was based on a peptide found in Gila monster saliva) to medications producing weight loss once only possible with surgery.
How a new drug reaches Canadians
Approval and access are separate steps in Canada, which is why a drug can be “approved” but still expensive or hard to get:
| Step | Who | What happens |
|---|---|---|
| 1. Submission | Manufacturer | Files a New Drug Submission with Health Canada, often after US or EU filings |
| 2. Review | Health Canada | Reviews safety, efficacy and quality; standard reviews take roughly a year |
| 3. Approval | Health Canada | Issues a Notice of Compliance; the drug can be sold by prescription |
| 4. Value assessment | Canada’s Drug Agency (CDA-AMC) | Recommends whether public plans should cover it, and at what price |
| 5. Price negotiation | pan-Canadian Pharmaceutical Alliance | Negotiates prices for public plans |
| 6. Listing | Each province | Decides whether and how to cover it; private insurers decide separately |
For obesity drugs, steps 4 to 6 have historically been the bottleneck: most provinces don’t cover drugs prescribed only for weight management, even after approval. That’s why many Canadians pay out of pocket or rely on private plans.
Brand names decoded
| Brand | Molecule | Company | Approved use |
|---|---|---|---|
| Ozempic | Semaglutide (injection) | Novo Nordisk | Type 2 diabetes |
| Wegovy | Semaglutide (injection or pill) | Novo Nordisk | Weight management; MASH (conditional, Canada) |
| Rybelsus | Semaglutide (pill) | Novo Nordisk | Type 2 diabetes |
| Apo-Semaglutide | Generic semaglutide | Apotex | Generic of Ozempic (Canada) |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes |
| Zepbound | Tirzepatide | Eli Lilly | Weight management; sleep apnea (US) |
| Saxenda | Liraglutide | Novo Nordisk | Weight management |
| Foundayo | Orforglipron | Eli Lilly | Weight management (US) |
| CagriSema | Cagrilintide + semaglutide | Novo Nordisk | Under FDA review |
| — | Retatrutide | Eli Lilly | Investigational |
When people say “Ozempic” casually, they often mean any drug in this class. Knowing the molecule helps you compare prices, generics and coverage.
FAQ
Tap a question to reveal the answer.
What is the newest weight loss drug?
In the US, the newest approvals are two pills: the Wegovy pill (oral semaglutide, December 2025) and Foundayo (orforglipron, April 2026). CagriSema has been filed, and retatrutide is expected to be filed in early 2027.
What is CagriSema?
A once-weekly injection combining semaglutide with cagrilintide, an amylin analog. In REDEFINE 1 it produced 20.4% average weight loss at 68 weeks, or 22.7% in people who took it as intended.
Is there a weight loss pill like Ozempic?
Yes. The US approved a higher-strength oral semaglutide (Wegovy pill) and orforglipron (Foundayo). Their weight loss, around 12% to 14%, is somewhat less than the strongest injections.
Which new weight loss drug is the strongest?
Retatrutide has shown the largest average weight loss in phase 3 trials, 28.3% at 80 weeks and 30.3% at 104 weeks, but it is not approved yet.
Is retatrutide better than CagriSema?
Retatrutide’s trial results show larger average weight loss, but the trials differ, and no head-to-head comparison exists. Tolerability and long-term outcomes will also matter.
When will the new weight loss pills be available in Canada?
They were approved in the US first. Canadian timing depends on Health Canada reviews; ask your pharmacist or check Health Canada’s Drug Product Database for current status.
What is orforglipron?
A small-molecule, non-peptide GLP-1 receptor agonist taken as a daily pill without food or water restrictions. It was approved in the US as Foundayo in April 2026.
Are newer weight loss drugs safer than Ozempic?
Not necessarily. Semaglutide has the longest safety record and proven cardiovascular benefit. Newer drugs share the same class risks and have less long-term data.
Why are weight loss drugs not covered after approval in Canada?
Approval by Health Canada and coverage are separate. Public coverage depends on value assessment by Canada’s Drug Agency, price negotiations and each province’s decision, and most provinces don’t cover drugs for weight management alone.
Related reading
- Retatrutide phase 3 results explained
- Weight loss injections in Canada
- Cagrilintide research guide
- Hair loss on GLP-1 drugs
References
- ACC. REDEFINE 1 and REDEFINE 2: greater weight loss with combined cagrilintide-semaglutide. July 2025. ACC
- AJMC. FDA approves oral semaglutide as first GLP-1 pill for weight loss. December 2025. AJMC
- Healio. FDA approves orforglipron, an oral GLP-1 for adults with obesity. April 2026. Healio
- Drugs.com. CagriSema FDA approval status. Drugs.com
- ACC. SYNCHRONIZE-1: survodutide led to significant weight loss in adults with obesity. June 2026. ACC
- AJMC. Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1. May 2026. AJMC
- HCPLive. BELIEVE: bimagrumab plus semaglutide preserves lean mass. June 2025. HCPLive
This article is general information about drug development, not medical advice. Approval status changes; confirm current availability with a pharmacist or Health Canada. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.